Literature DB >> 9109467

End-stage renal disease in African-American and white men. 16-year MRFIT findings.

M J Klag1, P K Whelton, B L Randall, J D Neaton, F L Brancati, J Stamler.   

Abstract

OBJECTIVE: To determine reasons for the 4-fold higher incidence of treated end-stage renal disease (ESRD) in African-American men compared with white men.
DESIGN: Prospective study.
SETTING: Men screened in 1973 through 1975 for entry into the Multiple Risk Factor Intervention Trial (MRFIT). PARTICIPANTS: A total of 332544 men (300645 white, 20222 African American, and 11677 other ethnic groups) aged 35 to 57 years. MAIN OUTCOME MEASURES: Incidence of ESRD assessed through 1990 using the Health Care Financing Administration national ESRD treatment registry and by surveillance for death from renal disease from data of the National Death Index and the Social Security Administration.
RESULTS: Over a mean follow-up of 16 years, age-adjusted ESRD incidence was 13.90 per 100000 person-years in white men and 44.22 per 100000 person-years in African-American men. Higher blood pressure and lower socioeconomic status were associated with higher incidence of ESRD in both ethnic groups. With adjustment for baseline age, systolic blood pressure, number of cigarettes smoked, previous myocardial infarction, diabetes, income, and serum cholesterol level, relative risk of ESRD in African-American men compared with white men was reduced from 3.20 to 1.87 (95% confidence interval, 1.47-2.39). Both higher systolic blood pressure and lower income in African-American men as compared with white men were particularly related to this reduced relative risk. Results were similar when hypertensive ESRD was used as the outcome.
CONCLUSION: Both higher blood pressure and lower income are associated with a higher incidence of ESRD in both white and African-American men. Disparities in blood pressure and socioeconomic status relate importantly to the excess risk of ESRD in African-American men compared with white men.

Entities:  

Mesh:

Year:  1997        PMID: 9109467

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  173 in total

Review 1.  What is the optimal strategy to intensify blood pressure control and prevent progression of renal failure?

Authors:  M Epstein; S Tobe
Journal:  Curr Hypertens Rep       Date:  2001-10       Impact factor: 5.369

2.  Issues of clinical trial design and data interpretations in hypertension.

Authors:  L H Kuller
Journal:  Curr Hypertens Rep       Date:  1999-08       Impact factor: 5.369

3.  Racial differences in postprandial mineral ion handling in health and in chronic kidney disease.

Authors:  Orlando M Gutiérrez; Tamara Isakova; Kelsey Smith; Michael Epstein; Neha Patel; Myles Wolf
Journal:  Nephrol Dial Transplant       Date:  2010-06-07       Impact factor: 5.992

4.  Racial differences in the incidence of chronic kidney disease.

Authors:  Paul Muntner; Britt Newsome; Holly Kramer; Carmen A Peralta; Yongin Kim; David R Jacobs; Catarina I Kiefe; Cora E Lewis
Journal:  Clin J Am Soc Nephrol       Date:  2011-11-10       Impact factor: 8.237

5.  Race and kidney disease: the scope of the problem.

Authors:  Keith C Norris; Lawrence Y Agodoa
Journal:  J Natl Med Assoc       Date:  2002-08       Impact factor: 1.798

6.  Ethnic specific recommendations in clinical practice guidelines: a first exploratory comparison between guidelines from the USA, Canada, the UK, and the Netherlands.

Authors:  D R Manna; M A Bruijnzeels; H G A Mokkink; M Berg
Journal:  Qual Saf Health Care       Date:  2003-10

7.  A high-density admixture map for disease gene discovery in african americans.

Authors:  Michael W Smith; Nick Patterson; James A Lautenberger; Ann L Truelove; Gavin J McDonald; Alicja Waliszewska; Bailey D Kessing; Michael J Malasky; Charles Scafe; Ernest Le; Philip L De Jager; Andre A Mignault; Zeng Yi; Guy De The; Myron Essex; Jean-Louis Sankale; Jason H Moore; Kwabena Poku; John P Phair; James J Goedert; David Vlahov; Scott M Williams; Sarah A Tishkoff; Cheryl A Winkler; Francisco M De La Vega; Trevor Woodage; John J Sninsky; David A Hafler; David Altshuler; Dennis A Gilbert; Stephen J O'Brien; David Reich
Journal:  Am J Hum Genet       Date:  2004-04-14       Impact factor: 11.025

8.  Racial and ethnic disparities in end stage renal disease: access failure.

Authors:  Yoshio N Hall
Journal:  Clin J Am Soc Nephrol       Date:  2012-01-05       Impact factor: 8.237

9.  Poverty and racial disparities in kidney disease: the REGARDS study.

Authors:  William M McClellan; Britt B Newsome; Leslie A McClure; George Howard; Nataliya Volkova; Paul Audhya; David G Warnock
Journal:  Am J Nephrol       Date:  2010-05-31       Impact factor: 3.754

10.  Targeted disruption of Cd40 in a genetically hypertensive rat model attenuates renal fibrosis and proteinuria, independent of blood pressure.

Authors:  Steven T Haller; Sivarajan Kumarasamy; David A Folt; Leah M Wuescher; Stanislaw Stepkowski; Manish Karamchandani; Harshal Waghulde; Blair Mell; Muhammad Chaudhry; Kyle Maxwell; Siddhi Upadhyaya; Christopher A Drummond; Jiang Tian; Wanda E Filipiak; Thomas L Saunders; Joseph I Shapiro; Bina Joe; Christopher J Cooper
Journal:  Kidney Int       Date:  2016-09-28       Impact factor: 10.612

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.